Elekta acquires Resonant Medical Inc., adding new solutions for image guided radiation therapy for treating cancer.

Elekta acquires Resonant Medical Inc., adding new solutions for image
guided radiation therapy for treating cancer.

Groundbreaking non-invasive, non-ionizing image guidance technology
enables exquisite visualization of soft tissue targets, provides
promising platform for next generation motion management.

Elekta today announced the acquisition of Resonant Medical Inc.,
Montreal Canada. Through this acquisition, Elekta adds exciting new
solutions for image guidance as well as highly skilled R&D resources in
the field of oncology imaging and motion management.

Resonant Medical Inc. (‘RMI') develops systems for image guided
radiation therapy of soft tissues using latest generation, 3-D
ultrasound technology. Subject to customary closing conditions, Elekta
will pay CAD 30 M in cash for the outstanding shares of RMI.

RMI's integrated software solutions have been developed in cooperation
with leading academic institutions to improve treatment accuracy for
cancer in the prostate, breast, liver, cervix, uterus, bladder as well
as head and neck. RMI's equipment is in daily clinical use in the US,
Canada, Italy, The Netherlands and Ireland and its research
collaborators are considered among the world leaders in their field.

Elekta's President and CEO Tomas Puusepp said “This is really exciting,
as it further enhances Elekta's state-of-the-art solutions in IGRT, by
adding RMI's leadership in soft tissue visualization and tracking,
especially focused on innovative solutions for breast and prostate
cancer. In addition, given Elekta's dedication to open architecture, the
technology will be made available to customers with other vendors'
equipment, making it possible to improve IGRT processes everywhere.”

RMI's current products will continue to operate with linear accelerators
from all manufacturers and provide outstanding image guidance for soft
tissue targets, especially in the breast and pelvic area, without
additional x-ray dose or using invasive implanted markers. They can add
high quality IGRT to the thousands of linacs in use today that do not
have integrated imaging systems, while the soft tissue detail is also
highly complementary to linacs already equipped with cone beam CT or MV
(portal) imaging.

In addition, RMI will provide useful additions to Elekta's MOSAIQ®
treatment planning solutions by displaying soft tissue structures, not
easily seen on X-ray computed tomography but in exact spatial
correlation with these CT images, and offering a suite of automatic
segmentation and contouring tools. 

“Elekta has gained an experienced development team with mature,
easy-to-use, stable clinical products. And the established sales and
marketing infrastructure of Elekta is the perfect foundation to further
introduce this valuable technology to the radiation oncology market.
Beyond just today however, the really exciting things are yet ahead as
we start to integrate RMI:s solutions with MOSAIQ and in the future with
our state-of-the art linear accelerators”, says Elekta's President and
CEO Tomas Puusepp.

RMI was founded in 2000 based on research from McGill University,
Montreal. The CEO of the company, Tony Falco, Ph.D. is one of the
founders and has over 15 years experience in advanced imaging
technology; clinical, product development, supply, and IP creation. The
company has 35 employees, of whom most are based in Montreal, Canada.

Tony Falco, CEO of RMI, says: “These are exciting times. RMI provides
solutions compatible with all vendors' simulators and linear
accelerators and together with Elekta's world-wide customer network it
provides us for the first time with the ability to improve clinical
standards on a global basis. In addition, being fully integrated with a
leading clinical solutions provider like Elekta makes it possible for us
to deliver truly unique integrated clinical solutions in the future, all
of which is important in improving patient care.”

Elekta expects to consolidate RMI into its accounts as from June 1st,
2010. The revenue for 2010/11 is expected to be around CAD 10 M.  The
transaction is forecasted to have a minor dilutive effect on reported
earnings per share during fiscal year 10/11 and be mildly accretive the
following fiscal year.

###

For further information, please contact:

Todd Powell, Executive Vice President, Elekta Software, Elekta AB
Tel: +1 650 823 3085, email: todd.powell@elekta.com

Time zone: PDT: Pacific Daylight

Stina Thorman, Vice President Corporate Communications, Elekta AB

Tel: +46 8 587 254 37, Mobile tel: +46 70 778 60 10 email:
stina.thorman@elekta.com (stina.thorman@elekta.com)

Time zone: CET: Central European

About Elekta

Elekta is a human-care company pioneering significant innovations and
clinical solutions for treating cancer and brain disorders. The company
develops sophisticated, state-of-the-art tools and treatment-planning
systems for radiation therapy and radiosurgery, as well as
workflow-enhancing software systems across the spectrum of cancer care.

Stretching the boundaries of science and technology, providing
intelligent and resource-efficient solutions that offer confidence to
both health-care providers and patients, Elekta aims to improve, prolong
and even save patient lives, making the future possible today.

Today, Elekta solutions in oncology and neurosurgery are used in over
5,000 hospitals globally, and every day more than 100,000 patients
receive diagnosis, treatment or follow-up with the help of a solution
from the Elekta Group. Elekta employs around 2,500 employees globally.
The corporate headquarter is located in Stockholm, Sweden, and the
company is listed on the Nordic Exchange under the ticker EKTAb. For
more information about Elekta, visit www.elekta.com.

About Resonant Medical

Established in 2000, Resonant Medical innovates and develops
revolutionary clinical solutions that are safe and gentle for the
patient while increasing the accuracy and precision of radiotherapy
cancer care. The company commercializes unique products that provide
better visualization of soft tissue anatomy throughout the radiotherapy
patient workflow. Resonant's Clarity system is the first and only
product to provide a non-invasive and radiation-free image guidance
solution for all conformal breast cancer treatments, as well as for the
treatment of other cancers such as prostate, cervix, uterus, liver,
bladder and head & neck. Resonant's technologies are available in cancer
centers throughout the U.S., Canada and Europe, helping make significant
improvements in patient care. The company is headquartered in Montreal,
Canada. For further information about Resonant, visit
www.resonantmedical.com.